Shrimp miR-965 induced the human melanoma stem-like cell apoptosis and inhibited their stemness by disrupting the MCL-1-ER stress-XBP1 feedback loop in a cross-species manner.
Cross-species gene expression regulation
Melanoma stem-like cells
Myeloid cell leukemia sequence 1 (MCL-1)
Shrimp miR-965
X-box-binding protein 1 (XBP1)
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
25 06 2020
25 06 2020
Historique:
received:
26
09
2019
accepted:
18
05
2020
revised:
29
04
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Melanoma is a type of aggressive skin cancer with a poor survival rate. The resistance to conventional therapy of this disease is, at least in part, attributed to its cancer stem cell population. However, the mechanism of survival and stemness maintenance of cancer stem cells remains to be investigated. Tumorsphere formation assay was used to study the stem-like property of melanoma stem-like cells (MSLC). Chromatin immunoprecipitation (ChIP), promoter luciferase reporter assay were included for exploring the role of MCL-1 in MSLC and electrophoretic mobility shift assay were used to evaluate the interaction between shrimp miR-965 and human Ago2 protein. Melanoma xenograft nude mice were used to study the inhibition of tumor development. In the present study, our results showed that myeloid cell leukemia sequence 1 (MCL-1) knocking down induced ER stress and apoptosis, and the expression reduction of stemness associated genes in MSLC, which implied a significant role of MCL-1 in MSLC. Further study indicated that ER stress agonist (tunicamycin) treatment in MSLC results in the translocation of XBP1, an ER stress sensor, into the nucleus to induce MCL-1 expression through direct binding to the - 313- to - 308-bp region of MCL-1 promoter. In addition, we found that a shrimp-derived miRNA (shrimp miR-965) could interact with the human Ago2 protein and suppressed the human MCL-1 expression by binding to the 3' UTR of MCL-1 mRNA, thereby inhibiting the MSLC proliferation and stemness in vitro and in vivo in a cross-species manner. In conclusion, we identified an important role of MCL-1-ER stress-XBP1 feedback loop in the stemness and survival maintenance of MSLC, and shrimp miR-965, a natural food derived miRNA, could regulate MSLC stemness and survival by targeting MCL-1 and disrupting the balance of MCL-1-ER stress-XBP1 feedback loop. In conclusion, this study indicated an important mechanism of the regulation of MSLC stemness and survival, otherwise it also demonstrated the significance of cross-species-derived miRNA as promising natural drugs in melanoma therapy.
Sections du résumé
BACKGROUND
Melanoma is a type of aggressive skin cancer with a poor survival rate. The resistance to conventional therapy of this disease is, at least in part, attributed to its cancer stem cell population. However, the mechanism of survival and stemness maintenance of cancer stem cells remains to be investigated.
METHODS
Tumorsphere formation assay was used to study the stem-like property of melanoma stem-like cells (MSLC). Chromatin immunoprecipitation (ChIP), promoter luciferase reporter assay were included for exploring the role of MCL-1 in MSLC and electrophoretic mobility shift assay were used to evaluate the interaction between shrimp miR-965 and human Ago2 protein. Melanoma xenograft nude mice were used to study the inhibition of tumor development.
RESULTS
In the present study, our results showed that myeloid cell leukemia sequence 1 (MCL-1) knocking down induced ER stress and apoptosis, and the expression reduction of stemness associated genes in MSLC, which implied a significant role of MCL-1 in MSLC. Further study indicated that ER stress agonist (tunicamycin) treatment in MSLC results in the translocation of XBP1, an ER stress sensor, into the nucleus to induce MCL-1 expression through direct binding to the - 313- to - 308-bp region of MCL-1 promoter. In addition, we found that a shrimp-derived miRNA (shrimp miR-965) could interact with the human Ago2 protein and suppressed the human MCL-1 expression by binding to the 3' UTR of MCL-1 mRNA, thereby inhibiting the MSLC proliferation and stemness in vitro and in vivo in a cross-species manner.
CONCLUSION
In conclusion, we identified an important role of MCL-1-ER stress-XBP1 feedback loop in the stemness and survival maintenance of MSLC, and shrimp miR-965, a natural food derived miRNA, could regulate MSLC stemness and survival by targeting MCL-1 and disrupting the balance of MCL-1-ER stress-XBP1 feedback loop. In conclusion, this study indicated an important mechanism of the regulation of MSLC stemness and survival, otherwise it also demonstrated the significance of cross-species-derived miRNA as promising natural drugs in melanoma therapy.
Identifiants
pubmed: 32586376
doi: 10.1186/s13287-020-01734-3
pii: 10.1186/s13287-020-01734-3
pmc: PMC7318764
doi:
Substances chimiques
MicroRNAs
0
Myeloid Cell Leukemia Sequence 1 Protein
0
X-Box Binding Protein 1
0
XBP1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
248Références
Curr Opin Oncol. 2013 Jan;25(1):50-1
pubmed: 23150341
Mol Cancer Ther. 2012 Aug;11(8):1672-82
pubmed: 22689530
Oral Oncol. 2011 Feb;47(2):83-91
pubmed: 21167769
J Dermatol Surg. 1976 May;2(2):108-10
pubmed: 932286
Cancer Res. 2017 Oct 15;77(20):5543-5553
pubmed: 28855207
Biochim Biophys Acta. 2011 Apr;1813(4):508-20
pubmed: 21146563
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
PLoS One. 2013 Aug 27;8(8):e73607
pubmed: 24014113
Am J Pathol. 1995 Jun;146(6):1309-19
pubmed: 7778670
FASEB J. 2005 Sep;19(11):1504-6
pubmed: 15972297
Cell Mol Life Sci. 2009 Apr;66(8):1326-36
pubmed: 19099185
Cell. 2007 Jun 29;129(7):1337-49
pubmed: 17604722
Cancer Biol Ther. 2006 Jul;5(7):756-9
pubmed: 16861911
Mol Cancer Res. 2009 Jul;7(7):989-99
pubmed: 19609002
G Ital Dermatol Venereol. 2018 Feb;153(1):56-67
pubmed: 28895666
Oncogene. 2009 May 7;28(18):1960-70
pubmed: 19330021
Cell Death Dis. 2010 May 06;1:e40
pubmed: 21364647
Genes Dev. 2005 Jun 1;19(11):1263-8
pubmed: 15937216
Curr Protoc Stem Cell Biol. 2013 Sep 20;26:3.8.1-3.8.10
pubmed: 24510792
Onco Targets Ther. 2013 Sep 04;6:1207-20
pubmed: 24043946
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
Trends Cell Biol. 2013 Jan;23(1):22-9
pubmed: 23026029
Cancer Lett. 2013 May 28;332(2):249-64
pubmed: 20732741
Cell Death Dis. 2018 Feb 7;9(2):194
pubmed: 29416012
Cell. 2001 Dec 28;107(7):881-91
pubmed: 11779464
Cell. 2009 Aug 7;138(3):592-603
pubmed: 19665978
Br J Cancer. 2013 Oct 1;109(7):1876-85
pubmed: 24008666
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Life Sci. 2010 Apr 24;86(17-18):631-7
pubmed: 20159023
Cancer Biol Ther. 2006 Oct;5(10):1355-6
pubmed: 17172809
Nat Rev Cancer. 2008 Jul;8(7):545-54
pubmed: 18511937
Mol Oncol. 2010 Oct;4(5):431-42
pubmed: 20580623
J Invest Dermatol. 2018 Jul;138(7):1609-1619
pubmed: 29408459
Genomics Proteomics Bioinformatics. 2009 Dec;7(4):147-54
pubmed: 20172487
Br J Cancer. 2002 Oct 7;87(8):815-24
pubmed: 12373593
Biochim Biophys Acta. 2004 Mar 1;1644(2-3):115-23
pubmed: 14996496
Cancer Lett. 2014 Feb 28;343(2):286-94
pubmed: 24120758
Genes Dev. 2012 Feb 15;26(4):305-11
pubmed: 22345513